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Abstract
Background: The widespread use of primary coronary intervention (PCI) has significantly
improved the prognosis of men presenting with acute coronary syndromes, but the cardiovas-
cular event rate among women has either levelled off or increased. The purpose of the present
prospective study was to compare the clinical outcome of women and men presenting with
ST-elevation myocardial infarction (STEMI) undergoing primary PCI with concomitant us-
age of GP IIb/IIIa inhibitors.
Methods: Between January 2006 and December 2007, 297 consecutive patients presenting
with STEMI were prospectively included in this single center investigation. Overall, 82 (27.6%)
women and 215 (72.4%) men were treated by PCI with additional bare metal stent implanta-
tion and a GP IIb/IIIa inhibitor.
Results: Women were significantly older (65 ± 10 vs 60 ± 12 years, p = 0.04), presented
with a smaller reference luminal diameter (2.83 ± 0.51 vs 2.94 ± 0.43, p = 0.03) and had
a higher prevalence of hypertension (68% vs 53%, p = 0.025) and obesity (30% vs 18%, p = 0.03).
The incidence of major adverse cardiac events (MACE, defined as death, re-myocardial in-
farction, target lesion revascularization and coronary artery bypass graft) during long-term
follow-up was similar in women and men (20% vs 26%, p = 0.29). Age, C-reactive protein,
platelet count and cardiogenic shock were identified as independent predictors for MACE,
whereas gender was not predictive.
Conclusions: In this study, female gender did not emerge as an independent predictor for
MACE, but women presenting with STEMI had a higher cardiovascular risk profile; this
emphasizes the need for a more extensive therapeutic strategy. Combination therapy with
primary PCI and GP IIb/IIIa inhibitors might mitigate gender-related differences in clinical
outcomes. (Cardiol J 2010; 17, 6: 580–586)
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GP IIb/IIIa, gender
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Introduction
Acute coronary syndromes (ACS), especially
ST-elevation myocardial infarction (STEMI), still
represent the commonest cause of death in the
western world [1]. The widespread use of primary
coronary intervention (PCI) has significantly im-
proved the prognosis of men, but, astonishingly, the
cardiovascular event rate among women has either
levelled off or increased [2–4]. In the case of throm-
bolysis, female sex is in fact associated with a worse
outcome compared to men [5–7]. The reason for the
discrepancy between men and women concerning
the benefit of reperfusion therapy in ACS remains
enigmatic and there is conflicting data on the im-
pact of the sex of a patient on outcomes in those
with acute myocardial infarction [8–12].
The administration of glycoprotein IIb/IIIa re-
ceptor (GP IIb/IIIa) inhibitors is a frequent treat-
ment for patients undergoing primary PCI. Accord-
ing to the American Heart Association (AHA)/
/American College of Cardiology (ACC) guidelines
for the management of patients with STEMI [13],
there is a class IIa recommendation (treatment rea-
sonable) for the GP IIb/IIIa inhibitor abciximab and
a class IIb recommendation (treatment may be con-
sidered) for the GP IIb/IIIa inhibitors tirofiban and
eptifibatide.
Nevertheless, there is little data available about
gender-related differences in clinical outcome in pa-
tients presenting with STEMI, and no data focus-
ing on gender-related differences for patients pre-
senting with STEMI who are treated with GP IIb/
/IIIa inhibitors. Therefore, the purpose of the
present prospective study was to compare the clini-
cal outcome of women and men presenting with
STEMI undergoing primary PCI with concomitant
use of GP IIb/IIIa inhibitors.
Methods
Patient selection
Between January 2006 and December 2007,
297 consecutive patients presenting with STEMI
were included in this study. In-hospital and long-
-term follow-up data were prospectively collected.
Patients with intravenous pre-hospital thromboly-
sis and patients with contraindications for a GP IIb/
/IIIa inhibitor were excluded. Hemodynamically
stable patients, as well as patients with cardiogenic
shock, were included. STEMI management was
carried out according to the AHA/ACC guidelines
[13]. All patients were treated by PCI with addi-
tional bare metal stent implantation and received
a GP IIb/IIIa inhibitor before the intervention.
Written informed consent was obtained from all
patients.
Procedural details and angiographic analysis
PCI was performed by the femoral approach.
Standard 5, 6 or 7 F guiding catheters and 0.014-inch
floppy guide wires were used. Implantation tech-
nique, balloon size and stent type were chosen at the
discretion of the physician. Predilation was per-
formed with a single low-pressure inflation (8 atm)
followed by stent implantation. High pressure stent
deployment (> 12 atm) was recommended. All
patients received unfractionated heparin (UFH)
(70 U/kg body weight) and 500 mg acetylsalicylic
acid before the procedure. Repeated 2,500 U bolus
doses of UFH were given during the procedure to
maintain an activated clotting time of > 250 s.
After diagnostic angiography, treatment with a GP
IIb/IIIa inhibitor (abciximab [ReoPro®] 0.25 mg/kg bo-
dy weight, followed by a 12 hour infusion at 0.125 µg/
/kg/min, eptifibatide [Integrilin®] 180 µg/kg body
weight, followed by a 18–24 hour infusion at 2.0 µg/
/kg/min, or tirofiban [Aggrastat®] 10 µg/kg body
weight, followed by an 18 hour infusion at 0.1 µg/
/kg/min) was initiated and followed by a 12–24 hour
infusion with concomitant UFH infusion. A loading
dose of 600 mg of clopidogrel was given before the
procedure, followed by 75 mg daily for the four weeks
using bare metal stents. Long-term treatment with
acetylsalicylic acid (100 mg/daily) was initiated in
all patients. Angiograms were obtained in multiple
projections at baseline and immediately after stent
placement. The angiograms were analyzed by quan-
titative coronary angiography (QCA) evaluated by
two independent observers. QCA was performed by
analyzing the digitally stored images before and af-
ter stent implantation, using Quantcor-software
(Siemens Medical Systems, Munich, Germany).
The coronary perfusion was graded using the
Thrombolysis In Myocardial Trial (TIMI) classifi-
cation [14]. In the case of total occlusions (TIMI 0),
the infarct-related lesion was clearly identified and
characterized after a guide wire was passed through
the thrombus (TIMI ≥ 1). The length of the steno-
sis was estimated with an electronic calliper and the
catheter tips were used for calibration. The diame-
ters of the proximal and distal reference segments
were averaged by the system to yield the reference
luminal diameter. The minimal luminal diameter
and the percentage of diameter stenosis were cal-
culated. The ‘door-balloon-time’, quantity of con-
trast agent as well as stent- and balloon-parameter
were recorded.
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Clinical data
STEMI was diagnosed according to the pres-
ence of two of the following criteria: persistent an-
gina pectoris for > 20 min; ST-segment elevation
of ≥ 0.1 mV in at least two standard leads or
≥ 0.2 mV in at least two contiguous precordial leads;
or the presence of a new left bundle branch block.
In-hospital serial electrocardiograms, coronary risk
factors, as well as peak creatine kinase (CK), tropo-
nin I (TNI), C-reactive protein (CRP) and platelet
count (PLT) levels were recorded. Long-term fol-
low-up was obtained by hospital consultation or
telephone contact and completed in all patients.
Major adverse cardiac events (MACE) were defined
as target lesion revascularization (TLR), coronary
artery bypass graft, re-myocardial infarction and
death.
Statistical analysis
Data is presented as mean ± standard devia-
tion (SD) for continuous variables and number and
percentage for categorical variables. Comparisons
of continuous variables between the groups were
performed using the unpaired Student t test (two
tailed) for normally distributed data and the Mann-
-Whitney U test for nonparametric data. Compari-
sons of categorical variables were carried out by c2
and Fisher’s exact tests. A value of p < 0.05 was
considered to be significant. To evaluate potential
confounding factors on patients with and without
MACE, multivariate logistic regression analysis
with backward elimination was performed. Age,
gender, smoking, hypercholesterolemia, hyperten-
sion, diabetes mellitus, obesity, familiar history of
coronary artery disease, cardiogenic shock, prior
myocardial infarction, previous angioplasty, previous
bypass surgery, CK, TNI, CRP and PLT were se-
lected as independent variables. Cumulative survival
rates of female and male patients are presented by
Kaplan-Meier curves. The calculations were per-
formed using InStat (GraphPad Software, San Diego,
California, USA) and SPSS software (SPSS-Soft-
ware GmbH, Munich, Germany).
Results
Baseline clinical data
The baseline clinical and laboratory data are
shown in Table 1. Eighty two females (27.6%) and
215 males (72.4%) presenting with STEMI and
undergoing PCI were included. There was a mod-
erate but statistically significant difference in mean
age (women: 65 ± 10 years, men: 60 ± 12 years,
p = 0.044). Arterial hypertension was more com-
mon in the women included (56 [68%] vs 115 [53%],
p = 0.025). Obesity also was a more common find-
ing in the women (25 [30%] vs 39 [18%], p = 0.027).
Men had undergone a previous angioplasty more
Table 1. Baseline clinical characteristics.
Female (n = 82) Male (n = 215) P
Age (years) 65 ± 10 60 ± 12 0.04
Risk factors
Smoking 34 (41%) 103 (48%) 0.36
Hypercholesterolemia 48 (59%) 139 (65%) 0.35
Hypertension 56 (68%) 115 (53%) 0.025
Diabetes mellitus 16 (20%) 50 (23%) 0.54
Obesity 25 (30%) 39 (18%) 0.03
Family history of CAD 10 (12%) 41 (19%) 0.17
Medical history
Cardiogenic shock 7 (9%) 32 (15%) 0.18
Prior myocardial infarction 9 (11%) 21 (10%) 0.83
Previous angioplasty 4 (5%) 33 (15%) 0.02
Previous bypass surgery 3 (4%) 12 (15%) 0.77
Laboratory parameters
CK max [U/L] 1347 ± 1742 1359 ± 1978 0.89
TNI max [ug/L] 50.6 ± 75.2 84.1 ± 484.6 0.80
CRP [mg/L] 12.12 ± 21.1 25.62 ± 46.0 0.10
PLT [109/L] 274.5 ± 69.3 261.6 ± 81.6 0.21
Data is presented as mean ± standard deviation or as number (%); CAD — coronary artery disease; CK — creatine kinase; TNI — troponin I;
CRP — C-reactive protein; PLT — platelet count
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often (4 [5%] vs 33 [15%], p = 0.02), but the medi-
cal history concerning prior myocardial infarction
and previous bypass surgery did not differ between
groups. The rate of patients with cardiogenic shock
was similar in both groups (7 [9%] vs 32 [15%],
p = 0.180), as were the maximum peak elevations
of CK, TNI, CRP and PLT (Table 1).
Angiographic characteristics
and procedural outcome
There was no difference between the alloca-
tion of the target vessel and the incidence of 1-, 2-
or 3-vessel disease (Table 2). The rate of adminis-
tration of the respective GP IIb/IIIa inhibitors (ab-
ciximab, eptifibatid, tirofiban) was similar in both
groups, as were procedural details such as quanti-
ty of contrast agent, number of stents, stent length,
stent diameter and maximal inflation pressure. QCA
results as diameter stenosis, minimal luminal diam-
eter and length of stenosis were comparable in both
groups, but women had a smaller reference lumi-
nal diameter at baseline (2.83 ± 0.51 vs 2.94 ± 0.43,
p = 0.03, Table 3). The rate of post-interventional
major bleeding complications including intracrani-
al hemorrhage (0 vs 1 [0.5%]), hematoma (6 [7%]
vs 13 [6%], p > 0.05), pseudoaneurysm (2 [2%] vs
3 [1%], p > 0.05), and the rate of blood product
transfusion (6 [7%] vs 14 [7%], p > 0.05) did not
differ significantly between females and males.
Clinical outcome
The in-hospital incidence of MACE (9 [11%]
vs 33 [15%], p = 0.46) did not differ significantly
between women and men (Table 4). Long-term fol-
Table 3. Procedural characteristics and quantitative coronary angiography.
Female (n = 82) Male (n = 215) P
Procedural characteristics
Door-to-balloon time [min] 2.79 ± 0.69 2.73 ± 0.53 0.72
Abciximab 50 (60%) 127 (59%) 0.79
Eptifibatid 16 (20%) 38 (18%) 0.74
Tirofiban 16 (20%) 50 (23%) 0.54
Number of stents used 97 250 1.00
Stent diameter [mm] 3.14 ± 0.27 3.14 ± 0.28 0.94
Stent length [mm] 16.9 ± 3.5 17.3 ± 3.9 0.49
Max. inflation pressure [atm] 14.6 ± 1.8 15.1 ± 1.9 0.09
Quantity of contrast agent [mL] 205 ± 80 214 ± 88 0.19
Baseline
Reference luminal diameter [mm] 2.83 ± 0.51 2.94 ± 0.43 0.03
Minimal luminal diameter [mm] 0.28 ± 0.43 0.26 ± 0.41 0.69
Diameter stenosis [%] 87 ± 15 89 ± 18 0.84
Length of stenosis [mm] 11.2 ± 6.4 10.8 ± 4.8 0.47
After stent implantation
Reference luminal diameter [mm] 3.1 ± 0.3 3.2 ± 0.5 0.86
Minimal luminal diameter [mm] 2.7 ± 0.6 2.8 ± 0.5 0.74
Luminal gain [mm] 2.4 ± 0.8 2.4 ± 0.7 0.32
Diameter stenosis [%] 10.8 ± 16.2 11.4 ± 14.7 0.86
Data is presented as mean ± standard deviation or as number (%)
Table 2. Angiographic characteristics.
Female Male P
(n = 82) (n = 215)
Target vessel
LAD 40 (49%) 79 (37%) 0.06
Left circumflex 8 (10%) 30 (14%) 0.44
Right 32 (39%) 98 (46%) 0.36
Saphenous vein graft 0 (0%) 5 (2%) 0.33
1-vessel disease 34 (41%) 78 (36%) 0.42
2-vessel disease 23 (28%) 66 (31%) 0.78
3-vessel disease 24 (29%) 69 (32%) 0.91
Baseline TIMI flow*
0–1 72 (88%) 198 (92%) 0.26
2 10 (12%) 17 (8%) 0.26
Final TIMI flow*
3 72 (88%) 91 (89%) 0.84
*According to the Thrombolysis In Myocardial Infarction (TIMI) trial;
LAD — left anterior descending
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low-up was obtained for all patients 213 ± 68 days
after stent implantation. The incidence of MACE
during long term follow-up was similar in both pa-
tient groups (16 [20%] vs 56 [26%], p > 0.29). Fi-
gure 1 shows the Kaplan-Meier survival curves ac-
cording to gender.
Patients developing MACE
At univariate analyses, patients developing
MACE were significantly older (65±10 vs 60 ± 12,
p = 0.003), had a higher incidence of obesity (19
[26%] vs 27 [12%], p = 0.005), presented with car-
diogenic shock more frequently (28 [39%] vs 11
[5%], p < 0.0001) and displayed a higher CRP and
PLT level. Female gender was not predictive for
MACE (16 [22%] vs 66 [29%], p = 0.29) (Table 5).
Following multivariate analysis, after adjustment
with the variables mentioned in the section on sta-
tistical analysis, the association of age (OR 1.03,
95% CI 1.00–1.07, p = 0.033), CRP (OR 1.00, 95%
CI 1.00–1.02, p = 0.022), PLT (OR 1.00, 95% CI
1.00–1.01, p = 0.020) and cardiogenic shock (OR
9.17, 95% CI 3.68–22.89, p < 0.001) with MACE
remained significant.
Discussion
This is the first study comparing the clinical
outcome of women and men presenting with STEMI
undergoing primary PCI with concomitant use of
GP IIb/IIIa inhibitors. According to the present results,
female gender was not associated with a higher rate
of MACE or other complications.
There have been several studies reporting that
women treated with thrombolysis and presenting
with ‘acute myocardial infarction’ have a worse out-
come than men [5–7]. In studies investigating pa-
tients presenting with ACS (patients with STEMI,
NSTEMI or instable angina) randomized controlled
trials have yielded conflicting results. Whereas the
TACTICS TIMI-18 trial suggested a clear benefit
of an early invasive approach without any obvious
gender-related difference [15], the FRISC-II [16]
and RITA-3 [17] trials reported that an early inva-
sive strategy resulted in a beneficial effect in men
that was not seen in women. From these studies,
no direct conclusions can be drawn concerning the
impact of GP IIb/IIIa inhibitors on gender. In the
FRISC-II and RITA-3 trials, only 10% of patients
received abciximab, whereas in the TACTICS
TIMI-18 trial, all patients received the GP IIb/IIIa
inhibitor tirofiban. Likewise, in our study, all pa-
tients received a GP IIb/IIIa inhibitor and no gen-
der-related difference in outcome was found. Im-
portantly, our results focus on the field of STEMI
in real clinical practice.
So far, there have been many fewer studies
investigating the impact of gender in patients pre-
senting with STEMI than in patients presenting
with ACS. One of these studies was performed by
De Luca et al. [18]. The authors reported a higher
mortality rate in women, but as in our study, female
Table 4. Clinical outcome.
Female Male P
(n = 82)  (n = 215)
In-hospital follow-up
Re-MI 0 2 (1%) 1.00
Death 6 (7%) 23 (11%) 0.51
CABG 2 (2%) 5 (2%) 1.00
TLR 1 (1%) 3 (1%) 1.00
MACE 9 (11%) 33 (15%) 0.46
Long-term follow-up*
Re-MI 0 8 (4%) 0.11
Death 6 (7%) 28 (13%) 0.22
CABG 2 (2%) 6 (3%) 1.00
TLR 8 (10%) 14 (7%) 0.33
MACE 16 (20%) 56 (26%) 0.29
*Cumulative data including in-hospital follow-up; MI — myocardial
infarction; CABG — coronary artery bypass graft; TLR — target lesion
revascularization; MACE — major adverse cardiac events
Figure 1. Kaplan-Meier survival curves according to
gender. Kaplan-Meier analysis estimates the rates of
death during in-hospital days and long-term follow-up.
Rates of death between women and men were not si-
gnificantly different (p = 0.46, log rank test). Small ver-
tical tick–marks indicate when patients dropped out of
the study.
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sex did not emerge as an independent predictor of
death. Similarly in other studies, female sex did not
emerge as an independent predictor of MACE [9,
10]. De Luca et al. [18] explained the higher mor-
tality rate in women by the smaller reference luminal
diameter and the higher prevalence of cardiovascu-
lar risk factors in women, a difference in presenta-
tion which has been confirmed by many other stud-
ies [5–9, 12]. We also found a consistently smaller
reference luminal diameter and a higher cardiovas-
cular risk profile in women. Unlike our study, the
use of GP IIb/IIIa inhibitors was not reported or
discussed. Previous data has suggested that the
greatest benefit from GP IIb/IIIa inhibitors is de-
rived by patients presenting at high risk (elevated
troponin levels) [19]. Further, it has been reported
that in patients with cardiogenic shock, the benefit
of GP IIb/IIIa inhibitors persists through long-term
follow-up [20]. It is possible that both of these at-
tributes have contributed to our results, consider-
ing that in the present study the incidence of car-
diogenic shock was relatively high (13%) and only
patients presenting with STEMI were included.
Further studies are necessary to confirm this be-
neficial effect, and to clarify whether GP IIb/IIIa in-
hibitors might be able to reduce gender-related dif-
ferences in women < 50 years old (which is a se-
parate risk factor for mortality in women presenting
with ACS [7]). In this study, only five women with
this characteristic pattern could be included.
In general, patients with ACS display increased
platelet activation and increased levels of inflam-
matory mediators, both correlating with the degree
of myocardial damage [21–23]. GP IIb/IIIa inhibitors
suppress platelet aggregation [24] and have anti-
inflammatory effects [25, 26]. Both mechanisms
may also have contributed to the beneficial effects
of GP IIb/IIIa inhibitors in this study and may have
mitigated gender-related differences in the vascu-
lar risk factor profile of the investigated patient
cohort. It remains to be clarified by further studies
whether these beneficial effects might also signifi-
cantly improve the clinical outcome in patients al-
ready pre-treated with prasugrel.
In patients presenting with ACS, advanced age,
female sex, history of bleeding and renal insufficien-
cy are independently associated with a higher risk of
bleeding [27]. In this study, the incidence of major
bleeding complications did not differ between wom-
en and men. Nevertheless, we emphasize the impor-
tance of adjusting antiplatelet medication dose for body
surface area to minimize bleeding complications.
Table 5. Incidence of major cardiac events during in-hospital and long-term follow-up.
Patient characteristic With MACE Without MACE RR 95% CI P
(n = 72)  (n = 225)
Age† 65.0 ± 10.4 60.3 ± 11.8 < 0.01*
Female 16 (22%) 66 (29%) 0.75 46–1.23 0.29
Risk factors
Smoking 29 (40%) 111 (49%) 0.75 0.50–1.14 0.22
Hypercholesterolemia 48 (67%) 144 (64%) 1.09 0.71–1.68 0.78
Hypertension 46 (64%) 125 (56%) 1.30 0.85–1.99 0.22
Diabetes mellitus 20 (28%) 46 (20%) 1.35 0.87–2.08 0.20
Obesity 19 (26%) 27 (12%) 1.96 1.29–2.97 < 0.01**
Familiar history of CAD 9 (13%) 42 (19%) 0.69 0.37–1.29 0.28
Medical history
Cardiogenic shock† 28 (39%) 11 (5%) 4.21 3.02–5.88 < 0.01***
Prior MI 9 (13%) 21 (9%) 1.27 0.71–2.29 0.50
Previous angioplasty 12 (17%) 25 (11%) 1.41 0.84–2.35 0.22
Previous bypass surgery 6 (8%) 9 (4%) 1.71 0.89–3.29 0.21
Laboratory parameters
CK max [U/L] 1829 ± 2740 1205 ± 1575 0.71
TNI max [ug/L] 166 ± 853 49 ± 89 0.37
CRP [mg/L]† 37.27 ± 61.0 17.54 ± 32.2 0.05
PLT [109/L]† 288.1 ± 99.1 257.8 ± 69.4 0.02
Data is presented as mean ± SD or as number (%); *p = 0.003; **p = 0.005; ***p < 0.0001; †Independent predictors of MACE at multivariate analyses;
RR — relative risk; CI — confidence interval; CAD — coronary artery disease; MI — myocardial infarction; CK — creatine kinase; TNI — troponin I;
CRP — C-reactive protein; PLT — platelet count
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Limitations of the study
The non-randomized design of this single cen-
ter investigation may have influenced the compa-
rative analysis. Similar to other studies, a higher
pre-hospital mortality of women and the exclusion
of patients receiving pre-hospital thrombolysis
could have affected our results. Therefore, caution
is needed in the interpretation of our data. Nonethe-
less, we consider it improbable that these limitations
have significantly influenced our main findings.
Conclusions
In this study, female gender did not emerge as
an independent predictor for MACE. But women
presenting with STEMI had a higher cardiovascu-
lar risk profile, which emphasizes the need for
a more extensive therapeutic strategy. Combination
therapy with primary PCI and GP IIb/IIIa inhibitors
might mitigate gender-related differences in clini-
cal outcome. New studies investigating patients
pre-treated with prasugrel should be performed, to
evaluate the clinical influence of the beneficial ef-
fects of GP IIb/IIIa inhibitors.
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